FAQ  /  Men's Hormone Health

Will I Have to Donate Blood or Get Phlebotomy on Testosterone?

What testosterone actually does to your blood count

---

Testosterone stimulates red cell production through several routes at once. It produces an initial rise in erythropoietin, the hormone that tells bone marrow to make red cells, and then appears to reset the relationship between erythropoietin and hemoglobin to a new balance point. In parallel it lowers hepcidin, the master regulator of iron availability, which makes more iron available for building red cells. The result is a predictable rise in hemoglobin and hematocrit.

The important word there is predictable, not uniform. In a study that gave men graded weekly doses of testosterone enanthate from 25 mg all the way up to 600 mg, with 61 young men and 60 men aged 60 to 75, hemoglobin and hematocrit rose in a linear, dose-dependent fashion in both groups, and more steeply in the older men. This is the single cleanest demonstration that the size of the effect tracks with the size of the exposure. It is also the reason that dose, and not a donation schedule, is the first lever worth reaching for.

How often this actually becomes a problem

---

Less often than the conversation around it suggests, and how much less depends heavily on how the testosterone is given.

In a retrospective series of 247 men on testosterone therapy followed for a median of about three years, 23 percent at some point exceeded a hematocrit of 50 percent and 5 percent exceeded 54 percent, the threshold where guidelines call for a change. Higher body mass index and a higher hematocrit before starting both predicted who would rise, and nearly half of the men who crossed 46 percent hit their peak within the first year, which is a useful argument for closer monitoring early and less frequent monitoring later.

The contrast between two large trials makes the exposure point better than any argument could. In TRAVERSE, which randomized 5,246 men to a topical testosterone gel, six participants, fewer than one percent, exceeded a hematocrit of 54 percent even after titration to the lowest available dose. In T4DM, which used injectable testosterone undecanoate, hematocrit reached 54 percent or higher in 22 percent of men receiving testosterone, and 5 percent stopped treatment because of it. Same drug class, same endpoint, wildly different rates. The difference is dose and delivery, not some inherent property of testosterone.

Where the "just donate blood" reflex came from

---

This is worth understanding, because the reflex is borrowed from a different disease.

Polycythemia vera is a myeloproliferative disorder, a bone marrow cancer in which red cell mass rises because the marrow has acquired a mutation driving it to overproduce. Thrombosis is the leading cause of illness and death in polycythemia vera, and therapeutic phlebotomy to a hematocrit target below 45 percent is a mainstay of treating it. That practice is well established and well justified in that disease.

Secondary erythrocytosis from testosterone therapy is not that disease. It is a normal marrow responding normally to a hormonal signal, and it reverses when the signal changes. Importing the treatment for a marrow cancer into the management of an expected pharmacologic effect is how the idea took hold that every man on testosterone will be donating blood indefinitely.

What the guidelines actually say

---

They say less about phlebotomy than the folklore implies, and they consistently put dose adjustment first.

The threshold that matters across professional bodies is a hematocrit of 54 percent. The American Urological Association recommends dose reduction or temporary discontinuation at or above that level. The Endocrine Society uses it as the point to stop therapy. The European Academy of Andrology describes a general consensus that above 54 percent requires withdrawal of therapy and sometimes phlebotomy. The British Society for Sexual Medicine says levels should remain below 54 percent and that dose adjustment or periodic venesection may be required to achieve it. The Endocrine Society of Australia puts it most plainly of all: elevated hematocrit can usually be managed by reducing the testosterone dose or frequency, and only rarely requires venesection.

Read that list for its structure. Every one of them treats the testosterone dose as the thing to change. Phlebotomy appears as a secondary option, hedged with words like sometimes and rarely. None of them describe routine donation as a maintenance feature of treatment.

Before reaching for phlebotomy, ask why the hematocrit is up

---

This is the part that gets skipped, and it is the part most likely to actually solve the problem.

Testosterone is not the only thing that raises red cell mass, and in a given man it may not even be the main thing. Low blood oxygen from any source drives the same erythropoietin response. That includes untreated obstructive sleep apnea, which is common in exactly the population being treated for low testosterone and frequently undiagnosed. It includes chronic lung disease and tobacco use. It includes living at altitude, where a higher hematocrit is normal adaptation rather than pathology. Dehydration raises the measured value without any change in red cell mass at all, simply by reducing the plasma the cells are suspended in, which is why a single number drawn on a dehydrated morning deserves a repeat before anyone acts on it. And higher body mass index predicted rising hematocrit in the cohort described above, which points back at the metabolic picture rather than at the prescription.

The review that examined this question most directly recommends precisely this order: lower the testosterone dose and target risk factors such as smoking and severe obstructive sleep apnea first, and only after that consider phlebotomy, through shared decision-making that acknowledges how uncertain its benefit is. A man who gets his sleep apnea treated and his dose adjusted may never need a phlebotomy appointment. A man who starts donating blood every eight weeks without anyone asking about his snoring has had a symptom managed and a cause ignored.

Why routine phlebotomy is not the harmless default it sounds like

---

Removing blood periodically sounds benign, and the fact that blood donation is a public good makes it sound doubly so. The clinical picture is less simple.

A 2024 review in Endocrine Connections examined the evidence base for therapeutic phlebotomy in testosterone-induced erythrocytosis and concluded that evidence supporting either its efficacy or its safety in this setting is lacking. The authors make a mechanistic argument worth understanding. Repeated phlebotomy works partly by depleting iron stores, which puts the brakes on red cell production by removing the raw material. It also lowers tissue oxygen tension. Both of those changes trigger biological pathways that may themselves influence clotting risk, and the authors argue these effects could offset or even override the benefit of correcting the number on the lab report. Their conclusion is not that phlebotomy is wrong. It is that the pros and cons deserve to be weighed rather than assumed, and that the decision should be a shared one.

Iron depletion also has its own symptom profile, including fatigue, weakness, breathlessness and a fast heart rate. Those symptoms are easy to attribute to the testosterone, or to the aging that brought a man in to begin with, which can lead to dose changes that were never actually needed. It is worth knowing that a man who feels worse after months of regular donation may be feeling the donation.

What about "microdosing"?

---

The term needs unpacking, because it is doing more marketing work than clinical work.

In pharmacology, microdosing means giving a dose far below the therapeutic range, the kind used in early exploratory studies to trace what the body does with a compound. That is not what the word means in testosterone marketing. There it usually means taking the same weekly total and splitting it into smaller, more frequent injections, often daily or every other day, and often subcutaneously. The total exposure is unchanged. Calling that a micro dose is a category error.

The idea underneath it is not silly, though, and deserves a fair hearing. Peak concentration does appear to matter. The dose-response study above shows the effect scales with exposure. A network meta-analysis of randomized trials found intramuscular testosterone enanthate and cypionate raised hematocrit more than transdermal patches, and the gap between TRAVERSE and T4DM described earlier points the same way. The most direct evidence comes from a comparison of 234 hypogonadal men treated with either intramuscular testosterone cypionate 100 mg weekly or a subcutaneous testosterone enanthate autoinjector at the same 100 mg weekly, a device specifically designed for a lower peak-to-trough ratio. At twelve weeks the subcutaneous group had significantly lower hematocrit and estradiol than the intramuscular group after adjusting for covariates. Same dose, same frequency, flatter curve, lower hematocrit.

Here is the distinction that matters. That study changed the delivery, not the frequency, and it was a cohort comparison rather than a randomized trial. What has not been demonstrated is that taking your existing weekly dose and chopping it into smaller more frequent injections prevents or corrects erythrocytosis. No trial has tested that endpoint. The closest available evidence points the other way: in a series of patients who had already developed erythrocytosis on testosterone cypionate, spacing the doses out had no effect on hemoglobin, hematocrit or testosterone level, while stopping treatment for three months did.

There is also a reason to be skeptical of the word itself. A 2026 content analysis in the Journal of Clinical Endocrinology and Metabolism reviewed 253 websites offering testosterone treatment across four languages and catalogued claims that depart from clinical guidelines. The claim that microdosing improves treatment outcomes appeared on about 12 percent of them and was classified as a non-guideline-based practice, with clinics in the United States making such claims more often than those elsewhere. When a dosing strategy shows up primarily in clinic advertising rather than in trial results, that is worth noticing.

So the honest position is that flatter testosterone levels are a reasonable thing to aim for, that delivery route and dose both influence how high hematocrit goes, and that the goal is the lowest effective exposure that actually resolves symptoms rather than adherence to a branded schedule. Lower peaks are a sensible hypothesis. They are not a proven fix, and no one should be told that a particular injection frequency will keep their hematocrit down.

Is this the same thing as having thick blood that causes clots?

---

No, and the difference is the subject of its own page here. The short version is that the clot concern attached to elevated hematocrit was inherited from polycythemia vera, where thrombosis genuinely is the central danger, and that testosterone-induced erythrocytosis is a different entity with different behavior.

A follow-up analysis of TRAVERSE tested specifically whether the rise in hematocrit during testosterone treatment was associated with clotting or cardiovascular events and found it was not. In fairness, general-population data do link higher hematocrit with a modestly higher risk of venous thromboembolism, which is part of why 54 percent functions as a threshold rather than a number to disregard entirely. The full evidence on that question, including what TRAVERSE found and where the original belief came from, is laid out in the page on testosterone and blood clots.

Dr. Darrell Wilcox · @wellnessdoc_4everyoung on Instagram

This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Hematocrit results require interpretation in the context of your own history, hydration, other medical conditions, and the rest of your laboratory work, and an elevated value can have causes unrelated to hormone therapy that deserve evaluation. Decisions about testosterone dosing, monitoring intervals, and whether phlebotomy is appropriate should be made with your own physician, and should not be changed on your own based on anything written here. Individual results differ from trial averages, and the studies described here were conducted in specific populations that may not match your own situation. Dr. Wilcox is licensed to practice in multiple states. See About for current licensure.